Correct Answer: D. Strontium ranelate
Strontium ranelate is the only antiresorptive agent with a dual mechanism: it simultaneously decreases bone resorption AND increases bone formation. This dual action distinguishes it from all other osteoporosis drugs. Mechanistically, strontium ranelate increases osteoblast proliferation and differentiation (via Wnt/β-catenin pathway activation) while suppressing osteoclast activity and promoting osteoclast apoptosis. The strontium ion itself is incorporated into bone mineral, increasing bone density. In Indian clinical practice, strontium ranelate is particularly valuable in postmenopausal osteoporosis and glucocorticoid-induced osteoporosis (common in India due to high TB prevalence requiring prolonged corticosteroids). Unlike bisphosphonates (which only inhibit resorption) or PTH analogs (which primarily stimulate formation), strontium ranelate's combined effect makes it uniquely effective. The drug is administered as 2 g daily orally. Its efficacy in reducing vertebral and non-vertebral fractures in Indian populations has been demonstrated, though cost remains a limiting factor in resource-limited settings.
Why the other options are wrong
A. Ibandronate — Ibandronate is a bisphosphonate that acts exclusively by inhibiting bone resorption through osteoclast suppression; it does NOT increase bone formation. Bisphosphonates are antiresorptive agents only. This is a classic NBE trap—students may confuse 'improving bone density' with 'dual mechanism.' Ibandronate is used in India for postmenopausal osteoporosis but lacks the anabolic component. B. Teriparatide — Teriparatide (recombinant PTH 1-34) is a pure anabolic agent that primarily increases bone formation by stimulating osteoblasts; it does NOT significantly decrease bone resorption. In fact, PTH analogs may transiently increase resorption. This is the opposite mechanism from what the question asks. Teriparatide is reserved for severe osteoporosis in India due to cost and injection route. C. Calcitonin — Calcitonin is a pure antiresorptive agent that inhibits osteoclast activity and bone resorption; it does NOT increase bone formation. While calcitonin is used for acute pain relief in osteoporotic fractures in India, it has no osteoanabolic effect. Its antiresorptive action alone makes it inadequate for the dual mechanism described in the question.
High-Yield Facts
- Strontium ranelate is the ONLY osteoporosis drug with dual action: ↓ resorption + ↑ formation simultaneously.
- Bisphosphonates (ibandronate, alendronate, zoledronate) = antiresorptive only; PTH analogs (teriparatide) = anabolic only.
- Strontium ranelate dose: 2 g daily orally; must be taken 2 hours away from food/calcium for absorption.
- Wnt/β-catenin pathway activation by strontium is the molecular basis for increased osteoblast differentiation and bone formation.
- In India, strontium ranelate is particularly useful in glucocorticoid-induced osteoporosis (common with prolonged anti-TB therapy).
- Strontium ranelate reduces both vertebral AND non-vertebral fracture risk in postmenopausal women—unique among antiresorptives.
Mnemonics
DUAL-SR Decrease resorption + Up formation = Anti + Lanabolic = Strontium Ranelate. Use this when comparing mechanisms of osteoporosis drugs. Mechanism Ladder Bisphosphonates (down arrow only) → Strontium ranelate (down + up arrows) → PTH analogs (up arrow only). Remember: only strontium has BOTH arrows.
NBE Trap
NBE pairs strontium ranelate with other osteoporosis drugs to test whether students understand the distinction between antiresorptive-only vs. dual-action agents. Students who know bisphosphonates improve bone density may incorrectly assume they also increase formation, leading them to choose ibandronate.
Clinical Pearl
In Indian TB-endemic regions, glucocorticoid-induced osteoporosis from prolonged anti-TB therapy is common. Strontium ranelate's dual mechanism makes it ideal for these patients—it not only prevents further bone loss but actively rebuilds bone, reducing fracture risk in a population already weakened by chronic disease.
_Reference: KD Tripathi Pharmacology Ch. 63 (Drugs for Bone Disorders); Harrison Principles of Internal Medicine Ch. 397 (Osteoporosis)_